MedTrace Logo

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

NCT01037036 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2014-01-10

No results posted yet for this study

Summary

The objective of this study is to investigate how the intraocular pressure (IOP)-lowering effect of the L-PPDS is altered by adjunctive Xalatan therapy.

Conditions

Interventions

DRUG

Latanoprost Punctal Plug Delivery System

To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.

DRUG

Xalatan

Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.

Sponsors & Collaborators

  • QLT Inc.

    collaborator INDUSTRY

  • Mati Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Oscar Cuzanni, MD, MSc · QLT Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-04-30
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01037036 on ClinicalTrials.gov